<DOC>
	<DOCNO>NCT00415584</DOCNO>
	<brief_summary>Secondary hyperparathyroidism persist follow successful renal transplantation cause high blood calcium , kidney dysfunction failure excessive bone loss among problem . If condition resolve , surgery frequently require remove parathyroid gland , inherent risk surgery . Cinacalcet , medicine use treat secondary hyperparathyroidism patient kidney disease , may effective treat condition renal transplant recipient . We study effect cinacalcet calcium , bone renal function 6 month treatment protocol .</brief_summary>
	<brief_title>Cinacalcet Treat Hypercalcemia Renal Transplant Recipients</brief_title>
	<detailed_description>Secondary Hyperparathyroidism renal transplant recipient cause abnormal bone mineral metabolism , result hypercalcemia detrimental renal function , cause renal dysfunction calcinosis . These patient often require parathyroidectomy correct hypercalcemia . Surgery without significant risk patient . Risks include vocal cord paralysis , protract hypocalcemia , cardiac arrhythmia , muscle cramp . In addition , parathyroidectomy associate subsequent renal impairment . Cinacalcet calcimimetic agent effective treatment secondary hyperparathyroidism patient renal failure well hypercalcemia parathyroid cancer . There report short term Cinacalcet use renal transplant recipient . Serum calcium improve patient . However , little known effect cinacalcet bone activity turnover . It know whether Cinacalcet cause low turnover bone activity adynamic bone disease . It know low turnover bone disease renal patient cause hypercalcemia bone become static unable respond everyday calcium load . We show adynamic bone develop renal transplant recipient variety condition . It known effect , , cinacalcet bone activity renal transplant recipient persistent secondary hyperparathyroidism . The purpose study determine effect Cinacalcet serum calcium , renal function bone histology renal transplant recipient . This prospective , open-label study . Stable adult renal transplant recipient least 3 month post renal transplant , hypercalcemic persistent hyperparathyroidism inappropriately elevate Parathyroid hormone eligible . Protocol procedure include baseline 6 month measurement bone mineral density , bone biochemical parameter , glomerular filtration rate , anterior iliac crest bone biopsy . Subjects start cinacalcet first biopsy . The medication titrate normalize serum calcium . Medication supply study . Serum electrolytes monitor indicate .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>renal transplant recipient least 3 month post transplant hypercalcemia hyperparathyroidism allergic cinacalcet , tetracycline . pregnancy medication utilize liver system cinacalcet Hcl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>hypercalcemia</keyword>
	<keyword>transplant</keyword>
</DOC>